Updates with share moves
** Shares of Telix Pharmaceuticals TLX.AX rise 2.8% to A$27.44
** Morningstar analysts expect TLX to receive a delayed regulatory approval, instead of a denial, for co's Pixclara, an imaging agent for glioma brain cancer
** Telix said on Monday that the U.S. Food and Drug Administration declined to approve its new drug application for Pixclara
** The FDA has requested additional clinical evidence to progress the application
** Brokerage expects the product to make first sales and contribute to earnings from 2026, instead of 2025
** FOrecasts no material effect on co over the medium term
** Stock rated "buy" on average; median price target stands at A$35, per data compiled by LSEG
** Stock last up 11.3%, YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.